Member Info for lukehere

https://www.youtube.com/watch?v=xQ5ZwrbX-Ik Another "killer" product.

It looks as though these might cover "next generation" Vamousse,Guardian etc formulations ,along with those for control of internal parasites and control of pet fleas and ticks,where proof of concept has already been established.

In my opinion the presentation does include some "WOW factor" elements of detail of which I was not aware. Given the obvious potential, the share price remaining so low is one of those mysterious anomalies that occur in the market from time to time. As icepick says,"exciting times".

My thanks to timbo003 over on ADVFN for his invaluable input,which included the following link to an investor presentation that accompanied Tuesdays interim results. http://www.tyratech.com/wp-content/uploads/2017/09/TyraTech-Investor-Presentation-091217.pdf

Thanks icepick for that information. Hopefully then,once validated, the PureScience products will switch from being a drain, to a generator of profitability. If hundreds of millions of chickens have already been treated,then the field trials must have been both large scale and costly. The continued fall in the SP over the past 12 months was a concern to me. Nevertheless,I retained the faith in the TyraTech business model + the BOD and kept adding. The future does indeed now look one for investors to savour.

Bruno Jactel,in thr Proactive podcast stated that very large producers had "adopted our technology" and that they had "used our product to treat 100s of millions of chickens". Even if the product cost just one cent to treat ten chickens,surely the interim figures would have more reflected this level of uptake. Could anyone(ivyspivey,your field ?)provide an answer as to why revenues do not seem to be impacted by what is claimed by our CEO to be massive usage of PureScience products. To be fair,the Interims did announce that post period end saw the ," Launch of a new PureScience™ product for the poultry and swine markets in the US." It all looks pretty exciting to me and with each and every product said to be performing above expectations,we could well see a surprise on the upside,come the finals,never mind any benefits accruing from the strategic review.

When "shareholder value" is delivered lospeculatore,it will accrue equally to both lines of stock. One obtains more shares via the TYR classification. Interestingly,the TYR line is currently far more liquid,albeit on a 38% spread,with MMs happy to deal in 500k blocks within the quote.. The gap between TYR and TYRU is not so pronounced at present.A few months ago it was possible to switch holdings and effect a net increase of 33% in total shares held. Each to his own though,for I am not advocating buying one against the other. I can well see the SP continuing to climb,on a managed basis,with my initial target being a recovery in the TYRU line to 2 pence, which even at that level only accords a derisory valuation to the company when one considers the topicality and growing recognition of the TyraTech IP.

Thanks for those thoughts ivyspivey. If the human heath division is available for disposal then I wonder what valuation it might attract. Potentially more than the current market cap I would suspect.

Bruno Jactel,in his presentation today,went far beyond the detail contained in the interim accounts. I found it particularly interesting that the global consumer company had carried out due diligence over a two year period before entering into the agreement which was the subject of a RNS on July 4th. Could it be that similar due diligence is underway in respect of TyraTech as a whole, rather than just the human health side as put forward by ivyspivey ? Whatever transpires,the future looks bright for those invested here.I already hold significant amounts of TYRU and TYR shares and intend to add again tomorrow as long as the price remains subdued.

Same old,same old... PI getting shafted as per.

http://www.lse.co.uk/share-regulatory-news.asp?shareprice=TYR&ArticleCode=701h9499&ArticleHeadline=Joint_Development_and_License_Agreement Envance ( joint venture between American Vanguard Corporation (NYSE: AVD) (AMVAC) which holds a 86.67% interest and TyraTech which holds 13.33%. AMVAC is also a 15.15% shareholder in TyraTech) has entered a Joint Development and License Agreement with a major global consumer products company (the "Corporation) to develop and commercialize a range of pest control household products based on TyraTech's nature-derived technologies. The Agreement which sub-licenses Envance's existing rights to TyraTech's intellectual property ("IP") and knowhow with applications in the consumer household pest control sector to the Corporation. The Agreement specifically excludes personal care products, which are the sole property of TyraTech, such as the Vamousse® range of head lice treatments; Guardian™ personal insect repellants; as well as Animal Health applications will,according to CEO Bruno Jactel,benefit Tyratech in at least three separate ways. Firstly all parties will share technology and expertise in the development of new products for use in controlling pests in the home environment, and new intellectual property created will be jointly owned. Significantly, TyraTech will gain the right to use the new IP in its own fields (personal care and animal health). Secondly,TyraTech will be entitled to a small share of the profit of Envance, derived from the royalties on the Corporation's net sales of these products. Separately, in recognition of the addition of further IP in the same household sector, Envance will pay TyraTech associated royalties and an additional upfront cash fee of $500,000 which will be used to fund normal working capital. Thirdly, it is envisaged that TyraTech will also be involved in the development of the new products in the first few years of the Agreement, which is being fully funded by Envance. TyraTech will receive a fee in relation to research and development services in line with the terms of its existing agreement with Envance." The Agreement sub-licenses Envance's existing rights to TyraTech's intellectual property ("IP") and knowhow with applications in the consumer household pest control sector to the Corporation. The Agreement specifically excludes personal care products, which are the sole property of TyraTech, such as the Vamousse® range of head lice treatments; Guardian™ personal insect repellants; as well as Animal Health applications. These benefits should serve to reduce TYRU R&D costs whilst broadening and strengthening its IP and serve to promote future profitability. These benefits seem to have passed under the market's/investors radar imo.

Dec 16th 2016 TyraTech, Inc. using EPIC/TICKER code LON:TYR had its stock rating noted as ‘Retains’ with the recommendation being set at ‘BUY’ this morning by analysts at Whitman Howard. TyraTech, Inc. are listed in the Basic Materials sector within AIM. Whitman Howard have set a target price of 9 GBX on its stock. This would imply the analyst believes there is now a potential upside of 452.1% from today’s opening price of 1.63 GBX. Over the last 30 and 90 trading days the company share price has decreased 0.19 points and decreased 0.36 points respectively.

http://www.proactiveinvestors.com/companies/news/123744/tyratech-inc-has-sizeable-opportunity-in-animal-health-market-says-whitman-123744.html This is joint broker Whitman Howard's 2016 note. I will post the 2017 detail once I gain access .

http://allenbycapital.com/research/research-tyratech_22_352808282.pdf An email provision secures the note. Estimated losses of US$ 1million for 2017 with break even forecast in 2018.

a shell-for Kin Wellness will be gone as will the useless BOD. If NW1 wants its £10 million back-as I would in their shoes-then they will be consulting with others in the Concert Party. Only time will tell,but we are not dead yet.imo.

Dipla had this interesting obsevation to make over on ADVFN. "Well, unless I'm mistaken just had a look at companies house for Kin Group Plc, under their latest 'confirmation statement'/annual return old money... the report was published 07/07/14, stamped 28/06/17 04/07/17 and is dated 20/06/17... Is it not a breach of regulations that its been dated/published pre-market knowledge of when suspension actually occurred later. The confirmation statement has a part non traded company or shares?! BoD in breach here?!"

In view of the Kin telephone number no longer "being recognised",I have written to the Company requesting information. .

https://www.youtube.com/watch?v=_1oaepNfA3I So there you have it from our Heidi

EGM to :- Replace BOD Announce radical new business plan + injection of assets Refinancing Share consolidation Relisting I wish !

On one hand, I wish I were not currently invested here,whilst on the other,I would not want to be out should NW1 be about to pull a KIN rabbit out of their hat.